SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-13-317170
Filing Date
2013-08-02
Accepted
2013-08-02 16:04:45
Documents
12
Period of Report
2013-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q d542045d10q.htm 10-Q 438404
2 EX-3.4 d542045dex34.htm EX-3.4 4414
3 EX-31.1 d542045dex311.htm EX-31.1 10407
4 EX-31.2 d542045dex312.htm EX-31.2 10445
5 EX-32.1 d542045dex321.htm EX-32.1 4151
6 EX-32.2 d542045dex322.htm EX-32.2 4194
  Complete submission text file 0001193125-13-317170.txt   4312049

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT kerx-20130630.xml EX-101.INS 313436
8 XBRL TAXONOMY EXTENSION SCHEMA kerx-20130630.xsd EX-101.SCH 25002
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE kerx-20130630_cal.xml EX-101.CAL 37223
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE kerx-20130630_def.xml EX-101.DEF 187564
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE kerx-20130630_lab.xml EX-101.LAB 280573
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kerx-20130630_pre.xml EX-101.PRE 219969
Mailing Address
Business Address 750 LEXINGTON AVENUE . NEW YORK NY 10022 212-531-5965
KERYX BIOPHARMACEUTICALS INC (Filer) CIK: 0001114220 (see all company filings)

IRS No.: 134087132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-30929 | Film No.: 131006544
SIC: 2834 Pharmaceutical Preparations